EFV/FTC/TDF-associated hepatotoxicity: A case report and review

AIDS Patient Care and STDs

Volumn 27, Issue 9, 2013, Pages 493-497

  Echenique, Ignacio A ^a   Rich, Josiah D ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; RITONAVIR; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG WITHDRAWAL; FEMALE; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER CELL DAMAGE; LIVER TOXICITY; PAIN; VIRUS LOAD; VOMITING;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG-INDUCED LIVER INJURY; FEMALE; HIV INFECTIONS; HUMANS; LIVER; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84883382777     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0008     Document Type: Article

References (50)

1. Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDS 2012;26:312-319
2. McKinnell JA, Willig JH, Westfall AO, et al. Antiretroviral prescribing patterns in treatment-naive patients in the United States. AIDS Patient Care STDS 2010;24:79-85
3. Mathias AA, Hinkle J, Menning M, Hui J, Kaul S, Kearney BP. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. J Acquir Immune Defic Syndr 2007;46:167-173
4. Stephan C, Dauer B, Khaykin P, et al. Quadruple nucleos (t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/ abacavir in heavily pre-treated HIV-1 infected patients: Salvage therapy or backbone only? Curr HIV Res 2009;7:320-326
5. Lattuada E, Lanzafame M, Carolo G, Gottardi M, Concia E, Vento S. Does tenofovir increase efavirenz hepatotoxicity? AIDS 2008;22:995
6. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003;23:173-182
7. Gao S, Gui XE, Deng L, et al. Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. Hepatol Res 2010;40:287-294
8. Bruck S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13:343-348
9. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study. J Acquir Immune Defic Syndr 2004;35: 492-502
10. Manfredi R, Calza L, Chiodo F. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin Trials 2005;6: 302-311
11. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31
12. Palmon R, Koo BC, Shoultz DA, Dieterich DT. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29: 340-345
13. Van Welzen B, Mudrikova T, Arends J, Hoepelman A. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients. HIV Med 2012;13:448-452
14. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based firstline antiretroviral therapy: A systematic review and metaanalysis. AIDS 2013 [Epub ahead of print January 22, 2013
15. Meynard JL, Lacombe K, Poirier JM, Legrand J, Morand- Joubert L, Girard PM. Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. J Antimicrob Chemother 2009; 63:579-584
16. Merchante N, Lopez-Cortes LF, Delgado-Fernandez M, et al. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS Patient Care STDS 2011;25:395-402
17. Neuman MG, Schneider M, Nanau RM, Parry C. HIV-antiretroviral therapy induced liver, gastrointestinal, and pancreatic injury. Int J Hepatol 2012;2012:760706
18. Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME. Acute liver failure associated with antiretroviral treatment for HIV: A report of six cases. J Hepatol 2002; 36:295-301
19. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV. Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: A lesson from hepatic cells. Autophagy 2011;7:1402-1404
20. Apostolova N, Gomez-Sucerquia LJ, Gortat A, Blas-Garcia A, Esplugues JV. Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survivalpromoting autophagy. Hepatology 2011;54:1009-1019
21. Yin XM, Ding WX, Gao W. Autophagy in the liver. Hepatology 2008;47:1773-1785
22. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 2010;160: 2069-2084
23. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009;23:2101-2106
24. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009;63:841-843
25. Li J, Menard V, Benish RL, et al. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment. Pharmacogenomics 2012;13:555-570
26. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother 2009;53: 2791-2798
27. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: An AIDS Clinical Trials Group study. J Infect Dis 2010;202:717-722
28. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: An adult AIDS clinical trials group study. Pharmacogenet Genom 2006;16:837-845
29. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genom 2009;19: 300-309
30. Heil SG, van der Ende ME, Schenk PW, et al. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit 2012; 34:153-159
31. Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis 2009; 200:955-964
32. Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6. *6 are associated with efavirenzbased HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: A prospective cohort study. Pharmacogenomics J 2012;12:499-506
33. Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA. The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 2012;64:803-833
34. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006;16:191-198
35. Ishii Y, Takeda S, Yamada H. Modulation of UDP-glucuronosyltransferase activity by protein-protein association. Drug Metab Rev 2010;42:145-158
36. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012;67:2213-2221
37. Kwara A, Lartey M, Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 2008;48:1032-1040
38. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol 2012;2012:137192
39. Kwara A, Tashima KT, Dumond JB, et al. Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother 2011; 55:3527-3533
40. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012;68:689-695
41. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosiscoinfected patients with CYP2B6 516TT genotype on rifampincontaining antituberculous therapy. AIDS 2011;25:388-390
42. Hsu O, Hill CJ, Kim M, Tan B, O'Brien JG. Decreased plasma efavirenz concentrations in a patient receiving rifabutin. Am J Health Syst Pharm 2010;67:1611-1614
43. Lanzafame M, Bonora S, Lattuada E, Vento S. Efavirenz dose reduction in HIV-infected patients. HIV Med 2012;13: 252-253
44. Fayet Mello A, Buclin T, Decosterd LA, et al. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir Ther 2011;16:189-197
45. van Luin M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr 2009;52:240-245
46. Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit 2013;35:71-77
47. Schouten JT, Krambrink A, Ribaudo HJ, et al. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis Mar 1 2010;50:787-791
48. Prosperi MC, Fabbiani M, Fanti I, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: A retrospective cohort study. BMC Infect Dis 2012;12:296
49. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012;26:1399-1401
50. Beck EJ, Mandalia S, Sangha R, et al. Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008. PLoS One 2012;7:e47376